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Breast cancer is a complex heterogeneous disease and is a leading cause of death in
women. Early diagnosis and monitoring progression of breast cancer are important for
improving prognosis. The aim of this study was to identify protein biomarkers in urine for
early screening detection and monitoring invasive breast cancer progression.
Method
We performed a comparative proteomic analysis using ion count relative quantification
label free LC-MS/MS analysis of urine from breast cancer patients (n = 20) and healthy con-
trol women (n = 20).
Results
Unbiased label free LC-MS/MS-based proteomics was used to provide a profile of abundant
proteins in the biological system of breast cancer patients. Data analysis revealed 59 uri-
nary proteins that were significantly different in breast cancer patients compared to the nor-
mal control subjects (p<0.05, fold change >3). Thirty-six urinary proteins were exclusively
found in specific breast cancer stages, with 24 increasing and 12 decreasing in their abun-
dance. Amongst the 59 significant urinary proteins identified, a list of 13 novel up-regulated
proteins were revealed that may be used to detect breast cancer. These include stage spe-
cific markers associated with pre-invasive breast cancer in the ductal carcinoma in-situ
(DCIS) samples (Leucine LRC36, MAST4 and Uncharacterized protein CI131), early inva-
sive breast cancer (DYH8, HBA, PEPA, uncharacterized protein C4orf14 (CD014), filaggrin
and MMRN2) and metastatic breast cancer (AGRIN, NEGR1, FIBA and Keratin KIC10).
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Preliminary validation of 3 potential markers (ECM1, MAST4 and filaggrin) identified was
performed in breast cancer cell lines by Western blotting. One potential marker MAST4 was
further validated in human breast cancer tissues as well as individual human breast cancer
urine samples with immunohistochemistry and Western blotting, respectively.
Conclusions
Our results indicate that urine is a useful non-invasive source of biomarkers and the profile
patterns (biomarkers) identified, have potential for clinical use in the detection of BC. Valida-
tion with a larger independent cohort of patients is required in the following study.
Introduction
Breast cancer (BC) is a major public health problem worldwide. Despite the widespread use of
mammographic screening, which has contributed to reduced mortality, BC is still the most
common form of cancer among women. It can only be detected using mammography if there
is a visible, detectible abnormality with architectural distortion or calcification, which corre-
lates with the presence of several hundred thousand tumor cells. Once BC has been biopsied
and the diagnosis has been confirmed pathologically, the tumor is surgically excised. The com-
plexity and heterogeneity of individual tumors play an important role in therapeutic decision
making. Pathological examination is still the gold standard for diagnosis and assessment of
prognostic indicators in BC which include tumor size, grade (degree of tumor cell differentia-
tion), presence or absence of positive lymph nodes (metastases), immunohistochemical expres-
sion of key proteins such as estrogen receptor (ER), progesterone receptor (PR) and HER2 [1].
Although advances in BC diagnosis have been made in the last decade, there are still many
BC patients who cannot be diagnosed in the early stages of disease or monitored adequately for
tumor recurrence using current techniques. To reduce morbidity and mortality from BC, novel
approaches must be considered for screening, early detection and prevention, as well as for
monitoring cancer progression or recurrence. The early detection of ductal carcinoma in-situ
(DCIS) or invasive breast cancer (IBC) may prevent the development of life threatening meta-
static disease. Additionally, monitoring metastatic progression could identify early BC recur-
rence and help guide therapeutic decision making.
Human urine is one of the most interesting and useful bio-fluids for clinical proteomics
studies. Advances in proteomics, especially in mass spectrometry (MS) [2,3] have rapidly
changed our knowledge of urine proteins which have simultaneously led to the identification
and quantification of thousands of unique proteins and peptides in a complex biological fluid
[4,5]. Proteomic studies of urine are highly informative, and have been successfully used to dis-
cover novel markers for cancer diagnosis and surveillance [6–9] as well as for monitoring can-
cer progression [10,11]. Technological development combined with the addition of urine
screening would increase the knowledge about patient status and further assist assessment and
treatment in clinical practice. Proteomic analysis of urine holds the potential to apply a non-
invasive method to identify novel biomarkers of BC. However, investigation of urinary proteins
from different stages of BC patients using a liquid chromatography tandem mass spectrometry
(LC-MS/MS) proteomic approach has not been reported to date.
In this study, we used a label free LC-MS/MS technique to test the feasibility of urine as a
source for BC biomarkers and identify the urinary proteins for BC diagnosis and monitoring
progression. One potential marker (extracellular matrix protein 1 (ECM1) previously identified
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and associated with BC), and two novel potential protein markers (MAST4-microtubule asso-
ciated serine/threonine kinase family member 4 and filaggrin) identified from BC urine were
validated in BC cell lines and MAST4 was validated in a small number of primary BC tissues
and in the individual human BC urine samples, demonstrating the link of these proteins with
BC. However, a larger cohort of BC patients’ samples is needed for the validation of the identi-
fied potential markers in the following studies. The proteins identified showed significant dif-
ferences in abundance between the different BC disease stages which provide a useful reservoir
of biomarkers for the detection of early and advanced BC.
Materials and Methods
Study design and ethics
In this pilot study, all the female BC subjects had received detailed diagnostic procedures, i.e. a
physical breast examination, mammography, ultrasound and biopsy or excision with a detailed
pathological report on the cancer. Ethics approval for the collection of human urine and tissue
samples was approved by the South Eastern Sydney Area Health Service Ethics Committee
(SEA HRCE) (#07/71Li). The study was designed and conducted in accordance with the ethical
principles and all participants signed informed consent forms. None of the subjects had received
any prior treatment, either endocrine or chemotherapy. The healthy disease free control group
(n = 20) were age matched with the BC patients (range 35–70 years, mean age, 51 ± 10.5 years).
Urine samples were collected prior to surgery while BC tissues and normal part of breast tissues
were collected after surgery (St George Private Hospital, Sydney, Australia). The collected sam-
ples were evaluated and grouped in the analysis according to histopathology report, after diag-
nosis. The breast carcinoma typing and grading were performed by a pathologist according to
theWorld Health Organization criteria [1]. The samples were grouped into 3 different BC
stages: DCIS (n = 6), early IBC (with or without axillary lymph node involvement, but no distant
metastases, n = 8), and metastatic breast cancer (MBC) (distant metastases to viscera or bone,
n = 6) along with a group of samples with benign breast disease (BBD) (n = 6). The histopathol-
ogy characteristics and clinical features are summarized in Table 1.
Urine sample collection and processing
Clean catch (no skin contamination), midstream 30–50 mL urine samples were collected in a
sterile tube and immediately transported on ice. The urine was centrifuged at 2000 x g (4000













DCIS 6 25–48 3 DCIS
IBC 5 9–32 2 or 3 Ductal or Lobular present + +/+ -
2 or 3 Ductal or Lobular present - +/- -
3 14–22
MBC 6 10–23 2 or 3 Ductal or Lobular present + +/+ -
2 or 3 Ductal or Lobular present + +/- +
10–24
BBD 6 - - Fibrocystic change,
fibroadenoma
- - - -
Notes:LN: Lymph Node involvement; +/-: positive involved/ negative not involved; Tumour grade 1–3 [1].
Abbreviations: DCIS: ductal carcinoma in-situ; IBC: invasive BC; MBC: metastatic BC; BBD; benign breast disease; ER: oestrogen receptor status; PR:
progesterone receptor status; HER2: human epidermal growth factor receptor status.
doi:10.1371/journal.pone.0141876.t001
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rpm), at 4°C for 10 min to remove insoluble materials and cellular debris. The supernatants
were aliquoted and frozen at -20°C and then transferred to -80°C for long term storage. All
samples were handled by the same standard operating procedures and processed for storage
within one hour of collection.
All urine samples had protein concentration and urine creatinine levels measured, and
abnormal samples were excluded from the study. The appropriate volume of urine samples
was then pooled within the appropriate group to ensure the same total concentration of pro-
teins for proteomics analysis. The pooled urine supernatants from each group were subjected
to total protein precipitation by 1:8 sample-solvent ratio of ice-cold (-20°C) acetone, mixed
and stored for 1 hour at −20°C, and then high speed centrifuged with high speed centrifugation
(HSC), 11,000 x g at 4°C for 30 min. The supernatants were removed and the pellets were fur-
ther air-dried.
To further precipitate and concentrate the proteins, the pellets were resuspended in 2 mL of
fresh TCA solution (concentrated: 10 g TCA in 10 mL Milli-Q H2O) in a 4:1 sample-to-solvent
ratio, vortexed, incubated at 4°C for 1 hour and then centrifuged with HSC at 4°C for 30 min.
After carefully discarding the supernatants, protein pellets were washed twice with ice-cold
acetone for 15 min, along with HSC at 4°C for 15 min. All pellets were air-dried as our pub-
lished method [12].
All protein pellets were resuspended in 100 μL of rehydration buffer (RB) solution (2 M
thiourea, 7 M urea, 40 mM Tris-base, 1% 3-[(3 cholamidopropyl) dimethylammonio]-1-pro-
panesulfonate (CHAPS), 50 mMDTT and 0.1% Bromothymol Blue) before use, and vigorously
vortexed to ensure the pellets were completely dissolved. The protein concentrations of sam-
ples were determined with 2-D Quant Kit method (GE healthcare-Life sciences. Product code
80-6483-56) following the manufacturer’s instructions.
Urine sample protein clean-up and digestion
The peptide fractions were enzymatically digested with trypsin. Lyophilized protein samples
were reconstituted with 25 μL of 50 mM Ammonium bi-carbonate (AMBIC) (pH 8). Trypsin
(12.5 ng/μL trypsin proteomic grade, Sigma-Aldrich, St. Louis, MO, USA) was added to a final
enzyme-to-protein ratio of 1:100 (w/w) and was incubated at 37°C overnight. The reaction was
stopped by acidifying the preparation to ~pH 3 using neat formic acid (FA). Samples were
dried in a vacuum centrifuge to concentrate the samples which were stored at -20°C. Following
trypsin digestion, the peptide samples were purified using Strong Cation exchange (SCX) and
C18 StageTips (Thermo Scientific, USA) following the manufacturer’s instructions.
LC-MS/MS analysis of urine sample
Label-free LC-MS/MS quantification was performed using an Orbitrap Velos (LTQ-Orbitrap,
Thermo Scientific, USA). All urine samples were run in triplicate. Peptides were reconstituted
in 10 μL of 0.1% FA and separated by nano-LC using an Ultimate 3000 HPLC and auto sam-
pler (Dionex, Amsterdam, Netherlands). The samples (0.6 μL, 2 μg total load) were loaded
onto a micro C18 pre-column (500 μm × 2 mm, Michrom Bio-resources, Auburn, CA, USA)
with Buffer A at 10 μL/min (2% ACN and 0.01% Heptafluorobutyric Acid (HFBA) in water).
After a 4-min wash, the pre-column was switched (Valco 10 port valve, Dionex) into line with
a fritless nano column (75 μm diameter × 12 cm) containing reverse phase C18 media (3 μm,
200Å Magic, Michrom Bio-resources). Peptides were eluted using a linear gradient of Buffer A
to Buffer B (98% ACN, 0.01% HFBA in water) at 250 nL/min over 60 min. High voltage (2000
V) was applied to a low volume tee (Upchurch Scientific, Oak Harbor, WA, USA) and the col-
umn tip positioned ~0.5 cm from the heated capillary (T = 280°C) of an Orbitrap Velos
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(Thermo Electron, Bremen, Germany) mass spectrometer. Positive ions were generated by
electrospray and the Orbitrap was operated in data-dependent acquisition mode. A survey
scan MS was acquired in the Orbitrap in the 350–1750m/z range with the resolution set to a
value of 30 000 atm/z = 400 (with an accumulation target value of 1 000 000 ions), with lock-
mass enabled. The 10 most intense ions (>5000 counts) with charge states +2 to +4 were
sequentially isolated and fragmented within the linear ion trap using CID with an activation
q = 0.25 and activation time of 30 milliseconds (ms) at a target value of 30 000 ions. Them/z
ratios selected for MS/MS were dynamically excluded for 30 seconds to prevent repetitive selec-
tion of the same peptide.
Label-free LC-MS quantitative profiling
MS peak intensities were analyzed using Progensis QI, LC-MS data analysis software (version
4.1, Nonlinear Dynamics, Newcastle upon Tyne, UK). Ion intensity maps from each run were
aligned to a reference map and ion feature matching was achieved by aligning consistent ion
m/z and retention times. The peptide intensities were normalized against total intensity (sam-
ple specific log-scale abundance ratio scaling factor) and compared between groups by one-
way analysis of variance (ANOVA, p 0.05 for statistical significance). Type I errors were con-
trolled by False Discovery Rate (FDR) with q value set at 0.02 [13,14].
MS/MS spectra were searched and identified against the human protein database Uni-Prot
database (downloaded January 2013) using the database search programMASCOT (Matrix
Science, London, UK, www.matrixscience.com). Parent and fragment ions were searched with
tolerances of ± 6 ppm and ± 0.6 Da, respectively. Searched peptide charge states were limited
to +2 to +4. Deamination (M), Oxidation. Phosphorylation was chosen as variable modifica-
tions. Only peptides with an ion score>25 were considered for protein identification. Proteins
were considered to be significantly different at p< 0.05; fold change>3.
Generation of the heat map
The area under curve (AUC) of all MS1 peaks generated from comparisons among different
stages of BC in urine (Progensis data) was normalised to the mean of all AUC using TIBCo
spotfire (Boston, MA, USA). The clustering method used is UPGMA and distance measure
was Cosine correlation in logarithmic scale for rows. Columns were clustered using a Ward’s
method with distance measured using Half Square Euclidean.
Cell lines and cell culture
The human primary breast cancer cell line (BT-474) and metastatic cell lines (MDA-MB-231,
MCF-7 and SK-BR-3) were obtained from the American Type Tissue Culture Collection
(ATCC, Rockville, MD). All tissue culture reagents were supplied by Invitrogen Australia Pty
Ltd (Melbourne, VIC, Australia), unless otherwise stated. The primary BC cell line (BT-474)
was maintained in Improved Minimal Essential Medium (IMEM) supplemented with 10%
heated-inactivated fetal bovine serum (FBS), 50 U/mL of penicillin and 50 μg/mL of streptomy-
cin. Other three metastatic BC cell lines (MDA-MB-231, MCF-7 and SKBR-3) cell lines were
cultured in RPMI-1640 supplemented with 10% FBS, 50 U/mL of penicillin and 50 μg/mL of
streptomycin. All cell lines were maintained in a humidified incubator at 37°C and 5% CO2.
Protein from each cell line was extracted. Briefly, cells with 80–90% confluency were rinsed
twice with Dulbecco’s phosphate-buffered saline (DPBS) (pH7.2), and then lysed in a buffer
containing 50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L Sodium chloride (NaCl), 0.1% SDS, 10
mmol/L NaF, 1 mmol/L Sodium orthovanadate (Na3VO4), 0.5% sodium deoxycholate, 1%
Triton X-100, and 1/12 (v/v) protease inhibitor cocktail (Sigma-Aldrich, Pty Ltd, Castle Hills,
Breast Cancer Urine Biomarkers for Diagnosis and Monitoring
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NSW, Australia). After a brief incubation for 5 min on ice, the lysates were collected and centri-
fuged at 14,000 rpm for 10 min at 4°C and the supernatants were collected and stored at -80°C
for Western blotting experiment.
Western blotting
Protein expression levels were determined by Western blotting analysis as previously described
[15]. Human urine protein pellets (following acetone/TCA extraction) were re-suspended in
rehydration buffer (25 mmol/L Tris-HCl (pH 8.0), 0.5% SDS). Briefly, total proteins were mea-
sured using a BCA assay kit (Thermo Scientific, Rockford, IL, USA). Proteins from human BC
cell lines and human urine samples were resolved on 4–20% Tris-Nupage gels (Invitrogen Aus-
tralia Pty Ltd, Melbourne, VIC, Australia) and transferred to polyvinylidene fluoride mem-
branes. Membranes were blocked with 5% bovine serum albumin (BSA) (Sigma-Aldrich,
Sydney, NSW, Australia) in Tris-buffer with 0.1% Tween-20 (TBS-T) for 1 h, and then incu-
bated with mouse anti-secretory glycoprotein (ECM1) monoclonal antibody (MAb) (1:500
dilution, Abcam, USA), rabbit anti-MAST4 polyclonal antibody (PAb) (1:1000 dilution,
Abcam, USA) and rabbit anti-filaggrin PAb (1:1000 dilution, Abcam, USA) at 4°C overnight
(o/n), followed by incubation in horseradish peroxidase (HRP)-conjugated goat anti-rabbit or
goat anti-mouse secondary antibodies (1:2000 dilution). Immunoreactive bands were detected
using enhanced chemiluminescence (ECL) substrate (Pierce Chemical Co, Rockford, USA),
and imaged using the ImageQuant LAS4000 system (GE Health care, USA). To confirm equal
loading of protein lysates, membranes were stripped (Restore Western Blot Stripping Buffer,
Pierce) and re-probed using housekeeping antibodies GAPDH (MAb: EDMMillipore) or β-
tubulin (MAb: Sigma-Aldrich Pty Ltd, Australia), then processed as above. Images were pro-
cessed in Adobe Photoshop.
Immunohistochemistry
Standard immunoperoxidase procedures were used to visualize MAST4 expression using our
published method [16]. Briefly, paraffin sections including BC tissues and normal breast tissues
were deparaffinised in xylene, followed by a graded series of alcohols (100%, 95%, and 75%)
and re-hydrated in water followed by Tris-buffered Saline (TBS) (pH 7.5). Slides were subse-
quently immersed in boiling 0.1 M citrate buffer (pH 6.0) for 30 min to enhance antigen
retrieval, treated with 3% hydrogen peroxide and then incubated with primary rabbit anti-
MAST4 PAb (1:100 dilution) o/n at 4°C. After washing with TBS, slides were incubated with
goat anti-rabbit IgG (Dako, North Sydney NSW, Australia) secondary antibody (1:100 dilu-
tion) for 45 min at room temperature. Sections were finally developed with 3,3’ diaminobenzi-
dine (DAB) substrate solution (Sigma-Aldrich, Pty Ltd, Castle Hills, NSW, Australia) as a
chromogen, then counterstained with hematoxylin and blued with Scotts Bluing solution. Con-
trol slides were treated in an identical manner, and stained with an isotype matched non-spe-
cific immuno-globulin as a negative control. MDA-MB-231 cell line was used as positive
control.
Assessment of immunostaining
Staining intensity (0–3) was assessed using light microscopy (Leica microscope, Germany) at a
x 40 objective as—(negative), + (weak), ++ (moderate), and +++ (strong) using our previously
published method [16]. Evaluation of tissue staining was done, independently, by two experi-
enced observers (JB and YL). All specimens were scored blind and an average of grades was
taken. If discordant results were obtained, differences were resolved by joint review and consul-
tation with a third observer, experienced in immunohistochemical pathology.
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Results and Discussion
Proteomic discovery of circulating urinary markers in human BC
Label-free LC-MS/MS quantification was used to characterize the differential expression of uri-
nary proteins in various human BC stages. The urine samples were analysed from patients with
DCIS, IBC, MBC, BBD and normal healthy control subjects (ANOVA p< 0.05; q<0.02). A
reverse database was also searched to determine protein level FDR. Using Progenesis software
to compare protein expression between all the samples, we identified a total of 166 proteins
with 1% FDR (for protein identification, determined by searching a reverse database).
Using the raw urine data and Tibco-spotfire software Inc. 2014, a biological heat map of
clusters from different stages of BC patients and normal health control subjects was produced.
The representative data are shown in Fig 1. This analysis demonstrates datasets as clustered
patterns which show an overview of the distribution of urine proteins represented according to
their expression.
The data obtained with Progenesis LC-MS analysis was then applied to calculate the fold
change (FC) as a normalised ratio for disease compared to healthy control subjects. This statis-
tical analysis revealed 59 significant urinary proteins in BC with>3-fold change relative to the
normal healthy control subjects. These protein profiles are all recorded in Table 2 and S1–S3
Tables. A review of the literature demonstrates that the 59 significant proteins changing in
abundance have not been detected in human urine in either BC or BBD. Several of these pro-
teins identified were previously reported in blood, tissue and human BC cell lines (associated
references are shown in Table 2 and S1–S3 Tables), supporting that these proteins detected are
associated with BC. Therefore, in this study we decided to focus on the unreported proteins
changing in abundance, and their biological significance in BC. In addition, several proteins
typically associated with plasma (CO3, KV101, ALBU, A1AG1, FETUA, LAC2, TTHY, A1BG,
Fig 1. Heat map analysis of urine proteins from BC patients and conrol subjects. Heat map and dendogram of the raw data of urinary proteins identified
up or down expression of urine proteins from different stages of BC patients and normal health control subjects.
doi:10.1371/journal.pone.0141876.g001
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CO6A1, FIBA, CERU and HAPT) which are known to be excreted in urine [17] were also
detected. These proteins are shown in the Table 2 and S2 and S3 Tables with protein spots
marked . Several of plasma associated proteins (except LAC2 and FIBA) were also found to be
associated with BC, further substantiating our findings.







Score Fold SL BC Ref. Non BC
Ref.
DCIS
CO3 P01024 Complement C3 * Ř 2 92 3.9 S [18–25]
CYTA P01040 Cystatin-A Ř 4 227 3.7 C [26] [27,28]
KV101 P01593 Ig kappa chain V-I region AG * Ř 4 385 5.3 MF [29]
LRC36 Q1X8D7 Leucine-rich repeat-contain protein 36 Đ 2 73 3.7 CM
MAST4 O15021 Microtubule-associated serine/ threonine-protein
kinase 4
3 73 4.2 C [30,31]
ALBU P02768 Serum albumin * Ř 44 1974 4.1 S [32,33]
CI131 Q5VYM1 Uncharacterized protein C9orf131 3 93 4.4 U
IBC
ANXA1 P04083 Annexin A1 Ř 6 334 3.0 C,
PM
[34–37]
DYH8 Q96JB1 Dynein heavy chain 8, axonemal 3 79 3.4 C
HBA P69905 Haemoglobin subunit alpha Đ 3 89 3.1 C [38,39]
IGHG2 P01859 Ig gamma-2 chain C region Ř 7 250 3.2 S [22]
ITIH4 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 Ř 10 523 14.0 S [19,40] [41,42]
TRFL P02788 Lacto transferrin Ř 2 100 17.6 S [43] [44]
NGAL P80188 Neutrophil gelatinase-assoc. lipocalin Ř 2 93 3.3 S [45,46]
PEPA P0DJD8 Pepsin A Đ 8 362 12.8 S PEPC
[47]
VTNC P04004 Vitronectin Ř 2 58 4.0 S [33,48,49] [50]
MBC
AGRIN O00468 Agrin Đ 4.5 S,
CM
[51]
A1AG1 P02763 Alpha-1-acid glycoprotein 1*Ř 4 182 4.4 S [52]
FETUA P02765 Alpha-2-HS-glycoprotein * Ř 103 3.5 S [53,54]
APOA4 P06727 Apolipoprotein A-IV Ř 2 3.6 S [55]
CAH1 P00915 Carbonic anhydrase 1Ř 5 276 3.6 Mit [32]
SULF2 Q8IWU5 Extracellular sulfatase Sulf-2 Ř 3 238 3.2 CS [56,57]
NEGR1 (+2) Q7Z3B1 Neuronal growth regulator 1 Đ 7 184 4.2 CM [58]
SPRL1 Q14515 SPARC-like protein 1 Ř 3 100 3.4 S [59] [60–64]
Notes: Accession ID, Human Accession identification;Uni-Prot ID, Protein identification based on the Protein knowledge base UniProtKB/Swiss-Prot ID
(http://www.uniprot.org);Pep ID, Assigned Peptides Identified;Score, Mascot score;SL, Sub-cellular location as annotated in UniProtKB. Fold: Fold
change for BC samples normalized against the healthy control. The proteins of interest showing biological significance are underlined. For ease of
navigation, all proteins reported in the literature associated with BC are marked Ŕ or with other disease marked Đ. Plasma Proteins reported in Normal
Urine*[17].
Abbreviations: C, Cytoplasm; CM, Cell membrane; CS, Cell surface; MF, Membrane fraction; Mit, Mitochondrion; PM, Plasma membrane; S, Secreted; U,
Unknown.
doi:10.1371/journal.pone.0141876.t002
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Classification of identified urine proteins in BC
The 59 significant urinary proteins (p<0.05,>3-fold) identified (see Table 2 and S1–S3 Tables)
were classified according to their subcellular locations based on the Uni-Prot entry information
available. Protein locations shown in Fig 2 demonstrate that 52% (32) of the proteins are
secreted, 18% (11) cytoplasmic, 24% (15) membrane-associated, and 6% (4) grouped as others
consisted of nuclear, mitochondrial, cell organelle or unknown sub-cellular origin. The major-
ity of significant BC related proteins detected are secreted and membrane associated in nature,
either tumor or host in origin but associated with the presence of disease.
Urine protein distribution in BC patients
To investigate novel urine biomarkers in BC, we wanted to identify proteins which are both
increasing and decreasing in abundance, and associated with BC prognosis. Our proteomics
screening data provided a list of signature proteins for BC (Table 2, and S1 Table) and benign
disease (S3 Table). Firstly, this signature list highlights 37 unique circulating proteins which
were found to be expressed only in specific stages of BC and not across all the urine samples.
These BC profiles included 24 up-regulated proteins (Table 2) and 12 down regulated proteins
(S1 Table). Additionally, 23 proteins were identified which appeared across the different BC
urine samples, some of which displayed similar patterns of protein expression in DCIS and
IBC (S2 Table).
Our findings in the current study indicate that several significant urinary proteins in the BC
samples had a strong relationship with BC stage and are potentially promising BC markers.
Our profile lists contained several makers which have already been investigated and are known
to be associated with BC (see S2 Table). Therefore, the aim of this study was to highlight the
novel additional proteins which are not yet reported. We found 3 abundant proteins were
Fig 2. The sub-cellular locations of the 59 significant BC urinary proteins (p<0.05, >3-fold). Protein locations illustrate that 52% are secreted, 24%
membrane-associated, 18% cytoplasmic, and 6% are either nuclear, mitochondrial, cell organelle or unknown sub-cellular origin.
doi:10.1371/journal.pone.0141876.g002
Breast Cancer Urine Biomarkers for Diagnosis and Monitoring
PLOS ONE | DOI:10.1371/journal.pone.0141876 November 6, 2015 9 / 20
associated with pre-invasive BC (i.e. DCIS patients) including Leucine-rich repeat-containing
protein 36 (LRC36), Microtubule-associated serine/threonine-protein kinase 4 (MAST4) and a
novel uncharacterised protein C9orf131 (CI131) (Table 2). Also in the DCIS samples, Secreto-
granin-1 was found to be decreased (S1 Table).
Invasive BC is a cancer stage that invades outside the basement membrane of the lobule or
duct into the breast tissue, and can then spread to lymph nodes and distant organs. Finding
markers to detect the cancer before it spreads would prevent life threatening metastatic disease.
Several of the proteins which we detected have been reported as markers of BC and include
ANXA1, Vitronectin, Lacto transferrin, ITIH4 and NGAL (see Table 2). In our findings, the
six unreported potential markers of early IBC are Dynein heavy chain 8 (DYH8), Haemoglobin
subunit alpha (HBA) and Pepsin A (PEPA>10 FC) (Table 2), along with uncharacterized pro-
tein C4orf14 (CD014,>200-fold), filaggrin (>30-fold) and Multimerin-2 (down>40-fold in
DCIS, S2 Table), which are markedly elevated in the IBC samples. Protein DYH8 was previ-
ously detected in serum of normal health subjects [65]. Although HBA was reported as a
potential serum biomarker in ovarian [39] and colon cancer [38], only hemoglobin subunit β
was reported to be elevated in the BC patients [19]. Notably, Desmoglein-1, Kallikrein-1, Kera-
tin, type II cytoskeleton 2 epidermal (K22E) and Poliovirus receptor (PVR) were all proteins
significantly down regulated in IBC (S1 Table). Desmoglein-1 was reported as a prognostic
marker in anal carcinoma [66]. However, only Desmoglein-3 was found to be associated with
BC cells [67]. Kallikrein-1 has not been assigned for a specific biological function, even though
Kallikrein-2 and 3 are serum and tissue markers for diagnosis and monitoring of prostate can-
cer and BC [68,69]. Poliovirus receptor (also called CD155/PVR) which was down regulated is
known to have a key role in motility during cancer cell invasion, migration [70] and cell adhe-
sion in BC cell lines [71].
MBC is a stage of the cancer which has spread to distant sites within the body. A detection
pattern for MBC could provide the opportunity for early therapeutic intervention. Our analysis
results provide a list of proteins with numerous proteins already linked to BC including
A1AG1, FETUA, APOA4, CAH1, SULF2 and SPRL1 (see Table 2). In MBC, the novel proteins
detected include AGRIN, and Neural growth regulator 1 (NEGR1) (Table 2), as well as Fibrino-
gen alpha chain (FIBA) and Keratin type 1 cytoskeleton 10 (KIC10) (S2 Table) which were
exclusively elevated in the MBC samples. Only nerve growth factor 1 (NEGF1) was previously
reported in relation to the survival and proliferation of BC cells [72,73]. Additionally, in this
group of patients, Vasorin and Vitelline membrane outer layer protein 1 homolog (VMO1)
were both down regulated (S1 Table).
Analysis of the differential expression patterns of urine samples across different stages of BC
highlights potential protein markers that can identify some similarities or difference between
DCIS and IBC. DCIS is a non-invasive process which can progress to IBC. If a biomarker or a
panel of biomarkers could be identified in DCIS stage, an early action taken may prevent IBC
occurrence. Therefore, the identified potential BC markers have clinical significance.
The 23 proteins listed in S2 Table include 3 potential progression markers of BC: immune
response proteins immunoglobulin (Ig) kappa chain V-I region WEA (KV118), lambda -2
chain C region (LAC2) and ECM1. Protein ECM1 was elevated in BC (S2 Table). ECM1 is a
secreted glycoprotein, previously reported to be associated with BC metastatic bone homing
[74] and plays an important role in BC progression [75]. High levels are detected in aggressive
tumorigenic cancer cell lines MDA435 [76], in ductal breast carcinomas [77] and its expression
is also correlated with poor prognosis [78] and metastatic potential in cancer [79]. In the cur-
rent study, this protein was detected in IBC urine samples and validated in primary and meta-
static BC cell lines, further confirmed its link with BC patients. This urine marker ECM1
demonstrates the potential for BC diagnosis and monitoring.
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Urine protein distribution in benign disease patients
Although some benign breast diseases are associated with increased risk of subsequent BC,
benign breast condition is generally considered as a noncancerous disorder. In such cases,
markers at this stage are important for early detection in high risk individuals and understand-
ing of disease progression. In this study, we also identified a list of unreported proteins of inter-
est in association with BBD (S2 and S3 Tables). The 6 up-regulated proteins uniquely found
only in BBD include FAM184A, transcription factor E2F8 and Cadherin-1 along with Ig-
response proteins kappa chain V-III region VG (KV309,>1000-FC), lambda like polypeptide
5 (IGLL5) (S2 Table), and Ig kappa chain V-I region BAN (KV122) (S3 Table). Several down
regulated proteins were also identified in the benign breast patients (S3 Table). The most signif-
icant benign breast protein identified was Nucleobindin-1, which has a 200-fold change (S2
Table). Nucleobindin-1 is a major intracellular calcium-binding protein previously detected in
colorectal cancer cells after treatment with anti-tumor compounds [80].
Ingenuity analysis of interaction networks of human urine proteins in BC
patients
To identify the major biologic pathways of BC urine involved, Ingenuity Pathway Analysis
(IPA) Software (IPA; Ingenuity1 Systems, www.ingenuity.com Release date: 05-02-2013, Inge-
nuity Systems, Redwood City, CA, USA) was used for canonical pathway enrichment analysis
and the derivation of mechanistic networks. The lists of proteins were uploaded directly into
IPA for analysis, and functional pathways or networks with the highest confidence scores were
then determined. Cell growth and proliferation analysis are shown in Fig 3. The proteins
detected from Table 2 and S1 and S2 Tables are found to be associated with tumor growth and
Fig 3. Ingenuity cell growth and proliferation analysis of the urine proteins detected in BC. A. The cell growth and proliferation analysis showing the
urine proteins detected in BC patients are associated with tumor growth and progression. B. The results demonstrating that the strong biological involvement
and the direct effect of these identified proteins have their roles in inhibition and proliferation of various cells in the body.
doi:10.1371/journal.pone.0141876.g003
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progression (Fig 3A), suggesting that these proteins are involved in the inhibition or prolifera-
tion of various cells in BC patients (Fig 3B). The enriched pathways associated with BC urine
are shown in S1 Fig while the best scored networks were selected are shown in Fig 4. Highly
interconnected networks are likely to represent significant biological functions associated with
BC progression.
Proteomics results from this study demonstrate that the proteins detected in BC urine are
involved in the LXR/RXR activation and acute-phase response pathways, which are active dur-
ing inflammation and/or as a contribution of the immune response to cancer. Other pathways
also enriched include production of nitric oxide and reactive oxygen species (ROS) in macro-
phages and IL12 signaling and production in macrophages (Fig 4). IPA highlighted cholesterol
metabolism as significant in our BC samples. Cholesterol is an essential structural component
of the cell membrane and proliferating cells. Cancer cells are believed to have increased
requirements for cholesterol. Cancer cells can increase lipid biosynthesis and uptake choles-
terol from the bloodstream [81]. It seems that LDL-cholesterol enriched systemic environment
promotes BC progression by activating key signaling pathways and modulating cell behaviour.
LDL-cholesterol signaling was shown to induce BC proliferation and invasion [82].
These canonical pathway results show that multiple pathways and networks are involved in
the systemic response to BC and that intrinsic and endocytosis signaling pathways play a role,
along with communication between the innate and the adaptive immune system. Increasing
evidence indicates that the immune response plays an important role in BC disease [83,84].
Therefore, these immune response proteins in urine have potential to be used as BC
Fig 4. Ingenuity pathway analysis showing the top enriched canonical pathways. The enrichment of canonical pathways in the significant up-regulated
urine proteins associated with BC.
doi:10.1371/journal.pone.0141876.g004
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biomarkers for diagnosis and monitoring. The interaction between these identified pathways
in patients’ urine and BC disease is complex and biologically significant. More efforts will be
put to study the roles and functions of these signaling pathways in BC in the future.
Validation of the identified potential urine markers in BC cell lines
To find an association of identified potential urine protein with human BC, one existing
marker-ECM1 and another two selected novel protein markers MAST4, and filaggrin were
evaluated in human primary BC cell line (BT474) and metastatic BC cell lines (MDA-MB-231,
MCF-7 and SK-BR-3) by Western blotting. As shown in Fig 5A, ECM1 and MAST4 were posi-
tive in all 4 BC cell lines and filaggrin was positive in the 3 metastatic BC cell lines, suggesting
the identified potential urine markers from BC patients, are closely associated with human BC.
Preliminary validation of identified potential marker MAST4 in human
primary BC tissues
To further investigate the clinical significance of our findings, we conducted immuno-histo-
chemistry (IHC) for preliminary validation of one novel protein marker MAST4 using a small
number of representative human primary BC tissue samples, including DCIS and IBC patients
and normal breast tissues. Our results indicate that MAST4 was positive in 80% (4/5) of IBC
and in 60% (3/5) of DCIS, respectively and no positive staining was seen in normal breast tis-
sues (5/5). The typical staining results are shown in Fig 5B. These findings further strengthen
the link of the identified potential urine marker with BC disease. Due to the limited number of
patients’ tissue samples, a lager sample size is required in the following study.
Preliminary validation of potential mark MAST4 in individual human BC
urine samples
In order to confirm MAST4 overexpression in the individual DCIS patients, the remaining BC
urine samples available were re-examined using Western blotting. Our results clearly indicate
that high levels of MAST4 expression were found in the individual DCIS urine samples and
low levels in IBC and MBC urine samples, while no expression was seen in the samples from
BBD patients and normal health control subjects (see Fig 6), further confirming that a strong
link exists between MAST4 protein and the DCIS urine samples identified with the LC-MS/
MS.
MAST4 is a protein-coding gene. The roles and functions of this protein in cancers have not
been reported so far. Differential expression of MAST4 was observed between the four different
cell lines. High level of MAST4 expression was found in BT474 cell line which is an aggressive
luminal B subtype, suggesting this protein could be used as a therapeutic target of interest for
future studies of endocrine resistance. Though proteomics screening detected MAST4 as a sig-
nificant increased marker in DCIS, our results from BC cell lines and human BC tissues suggest
that MAST4 may be also involved in BC progression, which is also in line with the positive
expression in the individual urine samples from IBC and MBC patients. A preliminary analysis
of publically available mRNA expression profiling data (Kaplan-Meier Plotter, an online sur-
vival analysis tool [85] http://kmplot.com/analysis/index.php?p = service&cancer = breast),
demonstrated that MAST4 expression is highly significantly correlated with survival in a
cohort of over 3,000 BC patients. Therefore, we plan to further investigate the MAST4 expres-
sion in a large independent cohort of BC patients and study its role in BC metastasis.
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Conclusions
Identification of new biomarkers in early and advanced BC is important in the prevention and
monitoring of disease progression and is a recently developed research area. MS is a very pow-
erful technique for comprehensive analysis of proteins. Collection of urine from patients is
Fig 5. Validation of identified potential urine proteins ECM1, MAST4 and filaggrin from BC patients in human BC cell lines and protein MAST 4 in
primary BC tissues. A. High level of MAST4 was found in the primary BC cell line (BT474) and medium levels of MAST4 were found in the metastatic BC
cell lines (MDA-MB231, MCF-7 and SKBR-3). High levels of ECM1 and filaggrin were found in the metastatic BC cell lines (MDA-MB231, MCF-7 and SKBR-
3) while low level of ECM1was seen in the primary BC cell line (BT474) and no filaggrin expression was detected in the primary BC cell line (BT474).GAPDH
was used as a loading control.B. Illustration of the positive expression of MAST4 in BC using immunohistochemistry. Moderate cytoplasmic expression of
MAST4 (++) were seen in the primary IBC (B1) and DCIS (B4) tumours (n = 5 for each stage of BC); there was no expression of MAST4 in the negative
controls for either IBC (B2) or DCIS (B5). No staining was seen for MAST4 in normal breast tissues (B3 and B6), (n = 5). Magnifications x 400 in B1, B2, B4
and B5; magnifications x 200 in B3; magnifications x 100 in B6. Brown indicates positive staining and blue indicates nuclei. All results were from 3
independent experiments (n = 3).
doi:10.1371/journal.pone.0141876.g005
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relatively easy and non-invasive, therefore making it an ideal candidate to sample for clinical
management of patients and to search for biomarkers.
Within BC publications, most studies have used MS technologies to analyse urine metabolo-
mic biomarkers. In this study, LC-MS/MS analysis was performed on urine samples from BC
patients, benign patients and healthy control subjects. Therefore the results of this comparative
discovery study provide a panel of novel significantly altered urinary proteins that are abun-
dant in pre-invasive and invasive BC, but have not yet been previously detected in urine or
other biological samples. These BC proteins identified provide further insight into the complex
signaling pathway interactions occurring during the progression of BC. Our study indicates
that the majority of the abundant BC urinary proteins detected are secreted proteins. The list
of novel up-regulated proteins detected (Table 2), provides information which could be used to
create a panel of targets which could form part of urine screening “dipstick” test for the detec-
tion of non-invasive and invasive BC.
Breast cancer cell lines are preclinical models that represent different breast tumor subtypes.
To link the potential of urine markers identified with BC disease, we validated one existing
marker and two novel biomarkers in human BC cell lines by Western blot analysis. We
Fig 6. Expression of MAST4 in the individual urine samples from BC patients and controls.Western blotting was performed on the remaining urine
samples from BC patients and control subjects to confirm the expression of MAST4.A.Overexpression of MAST4 was shown in the individual DCIS urine
samples (DCIS 1–5), weak expression in IBC1 urine sample and no expression in control urine samples.B. There was no MAST4 expression found in the
BBD urine sample but medium expression in IBC (IBC 2–5) and MBC urine samples (MBC 1–3). ß-tubulin was chosen as a loading control.
doi:10.1371/journal.pone.0141876.g006
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demonstrated significantly elevated expression of three interesting markers-ECM1, MAST4
and filaggrin in a panel of human BC cell lines and one marker MAST4 in a small group of
clinical BC tissue (Fig 5) and urine (Fig 6) samples, indicating their promise for further
investigation.
Urinary proteins can potentially provide a preliminary indication of the presence of BC dur-
ing screening and could assist with direct examination and pathology testing for final diagno-
sis. The development of a non-invasive test of BC risk has been a major goal for more than 20
years. In the current study, we present potential protein biomarkers that are related to BC stage
that can be used for early diagnosis and monitoring cancer progression in urine. These novel
protein markers in urine require to be further evaluated in BC tissues and an independent
group of BC urine samples to test their specificity and sensitivity for BC early diagnosis and
lead to potential applications in cancer surveillance and prevention.
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